EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
afatinib Sensitive: B - Late Trials
Thorac Cancer - 3 weeks (New B)
|
afatinib Sensitive: B - Late Trials
Thorac Cancer - 3 weeks - (New C3)
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
osimertinib Sensitive: A1 - Approval
|
osimertinib Sensitive: A1 - Approval
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
lazertinib Sensitive: A1 - Approval
|
lazertinib Sensitive: A1 - Approval
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
aumolertinib Sensitive: A1 - Approval
|
aumolertinib Sensitive: A1 - Approval
|
EGFR T790M
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR T790M
|
Lung Non-Squamous Non-Small Cell Cancer
|
osimertinib Sensitive: A2 - Guideline
|
osimertinib Sensitive: A2 - Guideline
|
EGFR T790M
|
LUAD
|
EGFR T790M
|
LUAD
|
erlotinib Sensitive: B - Late Trials
|
erlotinib Sensitive: B - Late Trials
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
erlotinib + ramucirumab Sensitive: B - Late Trials
|
erlotinib + ramucirumab Sensitive: B - Late Trials
|
EGFR T790M
|
LUAD
|
EGFR T790M
|
LUAD
|
gefitinib Sensitive: B - Late Trials
|
gefitinib Sensitive: B - Late Trials
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
bevacizumab Sensitive: B - Late Trials
|
bevacizumab Sensitive: B - Late Trials
|
EGFR T790M
|
LUAD
|
EGFR T790M
|
LUAD
|
osimertinib Resistant: C1 - Off-label
|
osimertinib Resistant: C1 - Off-label
|
EGFR T790M
|
Lung Cancer
|
EGFR T790M
|
Lung Cancer
|
osimertinib Sensitive: C1 - Off-label
|
osimertinib Sensitive: C1 - Off-label
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria
|
bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
rociletinib Sensitive: C2 – Inclusion Criteria
|
rociletinib Sensitive: C2 – Inclusion Criteria
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
ASP8273 Sensitive: C2 – Inclusion Criteria
|
ASP8273 Sensitive: C2 – Inclusion Criteria
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
ASK120067 Sensitive: C2 – Inclusion Criteria
|
ASK120067 Sensitive: C2 – Inclusion Criteria
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
osimertinib + ramucirumab Sensitive: C2 – Inclusion Criteria
|
osimertinib + ramucirumab Sensitive: C2 – Inclusion Criteria
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
olmutinib Sensitive: C2 – Inclusion Criteria
|
olmutinib Sensitive: C2 – Inclusion Criteria
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria
|
osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
lazertinib Sensitive: C2 – Inclusion Criteria
|
lazertinib Sensitive: C2 – Inclusion Criteria
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
anlotinib Sensitive: C2 – Inclusion Criteria
|
anlotinib Sensitive: C2 – Inclusion Criteria
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
furmonertinib Sensitive: C2 – Inclusion Criteria
|
furmonertinib Sensitive: C2 – Inclusion Criteria
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
abivertinib Sensitive: C2 – Inclusion Criteria
|
abivertinib Sensitive: C2 – Inclusion Criteria
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
D-0316 Sensitive: C2 – Inclusion Criteria
|
D-0316 Sensitive: C2 – Inclusion Criteria
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
SH-1028 Sensitive: C2 – Inclusion Criteria
|
SH-1028 Sensitive: C2 – Inclusion Criteria
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
osimertinib + anlotinib Sensitive: C2 – Inclusion Criteria
|
osimertinib + anlotinib Sensitive: C2 – Inclusion Criteria
|
EGFR T790M
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR T790M
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 inhibitor Resistant: C3 – Early Trials
|
PD-L1 inhibitor Resistant: C3 – Early Trials
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
EGFR inhibitor Resistant: C3 – Early Trials
|
EGFR inhibitor Resistant: C3 – Early Trials
|
EGFR T790M
|
LUAD
|
EGFR T790M
|
LUAD
|
bevacizumab + osimertinib Resistant: C3 – Early Trials
|
bevacizumab + osimertinib Resistant: C3 – Early Trials
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
Tyrosine kinase inhibitor Resistant: C3 – Early Trials
|
Tyrosine kinase inhibitor Resistant: C3 – Early Trials
|
EGFR T790M
|
LUAD
|
EGFR T790M
|
LUAD
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
APL-103 Sensitive: C3 – Early Trials
|
APL-103 Sensitive: C3 – Early Trials
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
WZ4002 Sensitive: C3 – Early Trials
|
WZ4002 Sensitive: C3 – Early Trials
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
gefitinib Resistant: C3 – Early Trials
|
gefitinib Resistant: C3 – Early Trials
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
erlotinib Resistant: C3 – Early Trials
|
erlotinib Resistant: C3 – Early Trials
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
afatinib + ruxolitinib Sensitive: C3 – Early Trials
|
afatinib + ruxolitinib Sensitive: C3 – Early Trials
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
cetuximab + brigatinib Sensitive: C3 – Early Trials
|
cetuximab + brigatinib Sensitive: C3 – Early Trials
|
EGFR T790M
|
LUAD
|
EGFR T790M
|
LUAD
|
afatinib Resistant: C3 – Early Trials
|
afatinib Resistant: C3 – Early Trials
|
EGFR T790M
|
LUAD
|
EGFR T790M
|
LUAD
|
osimertinib + ramucirumab Sensitive: C3 – Early Trials
|
osimertinib + ramucirumab Sensitive: C3 – Early Trials
|
EGFR T790M
|
Lung Cancer
|
EGFR T790M
|
Lung Cancer
|
EGFR inhibitor Resistant: C3 – Early Trials
|
EGFR inhibitor Resistant: C3 – Early Trials
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
bevacizumab + erlotinib Resistant: C3 – Early Trials
|
bevacizumab + erlotinib Resistant: C3 – Early Trials
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
bevacizumab + gefitinib Resistant: C3 – Early Trials
|
bevacizumab + gefitinib Resistant: C3 – Early Trials
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
osimertinib + APG-1252 Sensitive: C3 – Early Trials
|
osimertinib + APG-1252 Sensitive: C3 – Early Trials
|
EGFR T790M
|
LUAD
|
EGFR T790M
|
LUAD
|
brigatinib Sensitive: C3 – Early Trials
|
brigatinib Sensitive: C3 – Early Trials
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
BPI-7711 Sensitive: C3 – Early Trials
|
BPI-7711 Sensitive: C3 – Early Trials
|
EGFR T790M
|
LUAD
|
EGFR T790M
|
LUAD
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR T790M
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR T790M
|
Lung Non-Squamous Non-Small Cell Cancer
|
ABCP Sensitive: C3 – Early Trials
|
ABCP Sensitive: C3 – Early Trials
|
EGFR T790M
|
Gallbladder Cancer
|
EGFR T790M
|
Gallbladder Cancer
|
erlotinib Sensitive: C4 – Case Studies
|
erlotinib Sensitive: C4 – Case Studies
|
EGFR T790M
|
Pancreatic Cancer
|
EGFR T790M
|
Pancreatic Cancer
|
erlotinib Resistant: C4 – Case Studies
|
erlotinib Resistant: C4 – Case Studies
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
APG-1252 Sensitive: D – Preclinical
|
APG-1252 Sensitive: D – Preclinical
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
osimertinib + DC101 Sensitive: D – Preclinical
|
osimertinib + DC101 Sensitive: D – Preclinical
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
amivantamab-vmjw Sensitive: D – Preclinical
|
amivantamab-vmjw Sensitive: D – Preclinical
|
EGFR T790M
|
LUAD
|
EGFR T790M
|
LUAD
|
gefitinib + PF-03084014 Sensitive: D – Preclinical
|
gefitinib + PF-03084014 Sensitive: D – Preclinical
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
MTI-31 Sensitive: D – Preclinical
|
MTI-31 Sensitive: D – Preclinical
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
neratinib + PF-05212384 Sensitive: D – Preclinical
|
neratinib + PF-05212384 Sensitive: D – Preclinical
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
neratinib Sensitive: D – Preclinical
|
neratinib Sensitive: D – Preclinical
|
EGFR T790M
|
Lung Cancer
|
EGFR T790M
|
Lung Cancer
|
BMS-722782 Sensitive: D – Preclinical
|
BMS-722782 Sensitive: D – Preclinical
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
Compound 6a Sensitive: D – Preclinical
|
Compound 6a Sensitive: D – Preclinical
|